The tumor microenvironment (TME) consists of a complex mix of cellular and non-cellular components, including immune cells, stromal cells, extracellular matrix, cytokines, and growth factors. These elements interact with tumor cells to influence tumorigenesis, growth, invasion, and metastasis. Long noncoding RNAs (lncRNAs)—a class of non-coding RNAs longer than 200 nucleotides—have attracted considerable attention for their roles in regulating gene expression at the epigenetic, transcriptional, and post-transcriptional levels. Emerging evidence suggests that lncRNAs are crucial in shaping the TME by modulating processes such as immune evasion, angiogenesis, metabolic reprogramming, and the maintenance of cancer stem cells. This review provides an overview of the current understanding of lncRNAs in the TME, focusing on their involvement in key signaling pathways and cellular interactions that drive tumor progression. We discussed how lncRNAs contribute to extracellular matrix remodeling, facilitate communication between tumor and stromal cells, and regulate immune cell infiltration and function within the TME. Additionally, we explore the potential of lncRNAs as biomarkers for early cancer detection and prognosis, as well as their promise as therapeutic targets to disrupt tumor-microenvironment crosstalk. The review also addresses challenges in targeting lncRNAs therapeutically, such as ensuring specificity, minimizing off-target effects, and achieving effective in vivo delivery of lncRNA-targeted therapies. Strategies to overcome these challenges include the development of highly specific lncRNA knockout technologies and the use of advanced delivery systems, such as nanoparticles and viral vectors, to precisely target tumor-associated cells. Overall, this review underscores the significant role of lncRNAs in the TME and their potential as novel tools for enhancing cancer diagnosis and treatment. By elucidating the multifaceted roles of lncRNAs in the TME, we aimed to provide insights that could lead to more effective, targeted therapeutic strategies, ultimately advancing cancer research and improving patient care.

Moffitt Cancer Center has launched The ImmunoVerse, a new podcast hosted by President and CEO Patrick Hwu, M.D. A world-renowned physician-scientist and tumor immunologist, Hwu will bring immunotherapy discoveries to life through the voices of those advancing the groundbreaking field.

NUS Medicine study uses AI to modify drug doses for personalised cancer treatment

Today, 24 April 2025, marks the first-ever World Hormone Day, a global campaign to raise awareness of the vital role of hormones in human health. Under the banner of #BecauseHormonesMatter, the endocrine community is sharing the small steps everyone can take to improve hormone health and calling on policymakers to prioritise endocrine health in health and research policies.

EXPLORER total body PET scanner is creating a new way to visualize the protective barrier to the brain to reveal impacts from cancer and other diseases.

Yuze “Alice” Sun, an electrical engineering professor, has been elected to The University of Texas at Arlington’s Academy of Distinguished Researchers for her contributions to technologies critical to health care, environmental monitoring and national defense.

The antimalarial drug mefloquine could help treat genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy and some cancers.